# A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma

> **NCT02777827** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 30 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Abediterol 0.156 μg
- **DRUG:** Abediterol 2.5 μg
- **DRUG:** Abediterol 0.05 μg
- **DRUG:** Abediterol 0.156 μg
- **DRUG:** Abediterol 2.5 μg
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02777827
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-21
- **Primary completion:** 2016-11-29
- **Final completion:** 2016-11-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2019-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02777827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02777827, "A Single Dose PD & PK Study With Two Formulations of Abediterol in Patients With Asthma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02777827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*